LEGN

Legend Biotech Corp LEGN

NasdaqMid CapHealthcare

13F Pro quality score

Rank #2,485 of 2,925

Why it scores 30Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$973.54M

Quarter to Dec 31

Net income

$-30.82M

Quarter to Dec 31

Free cash flow

$-24.57M

Quarter to Dec 31

Operating margin

-2.0%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$2.98B total
FMR LLC
$840.23M+13.2%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$235.01M+5.9%
SUVRETTA CAPITAL MANAGEMENT, LLC
$204.18M-6.7%
Hillhouse Capital Advisors, Ltd.
$172.83M0.0%
BlackRock, Inc.
$136.50M+0.9%
WESTFIELD CAPITAL MANAGEMENT CO LP
$127.94M-23.1%
GOLDMAN SACHS GROUP INC
$105.77M+150.1%
Point72 Asset Management, L.P.
$88.84M-20.8%
Kynam Capital Management, LP
$86.67M+90.4%
Assenagon Asset Management S.A.
$55.31MNew
Artisan Partners Limited Partnership
$45.04M-30.8%
STATE STREET CORP
$43.29M0.0%
Capital International Investors
$41.03M+119.3%
MORGAN STANLEY
$40.27M+131.2%
Soleus Capital Management, L.P.
$34.80MNew
Davern Capital Partners, LP
$34.41M-9.4%
DRIEHAUS CAPITAL MANAGEMENT LLC
$33.47MNew
RENAISSANCE TECHNOLOGIES LLC
$28.89M+91.7%
Ghisallo Capital Management LLC
$28.88MNew
MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC
$26.49M-0.9%
JOHNSON & JOHNSON
$23.53M0.0%
IvyRock Asset Management (HK) Ltd
$23.13M-0.4%
EcoR1 Capital, LLC
$23.10MNew
JPMORGAN CHASE & CO
$22.52M+166.0%
Squarepoint Ops LLC
$22.22M+60.4%
See all 219 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2025
EDGAR

Net Income

Q4 2025
EDGAR

Operating Margin

Q4 2025
EDGAR

ROIC

Q4 2025
EDGAR

Free Cash Flow

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/LEGN

Earnings Per Share

13fpro.ai/company/LEGN

Loading ratio trend…

LEGN key financials by period

Reported revenue, net income and operating margin by fiscal year, from Legend Biotech Corp's annual filings on SEC EDGAR.

Legend Biotech Corp reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.0B$-296.8M-13.3%
FY 2024$627.2M$-177.0M-49.3%
FY 2023$285.1M$-518.3M-185.2%
FY 2022$117.0M$-446.3M—
FY 2021$68.8M$-403.6M—
FY 2020$75.0M$-266.4M—
Source: LEGN filings on SEC EDGAR →

Companies similar to LEGN

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

LEGN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Legend Biotech Corp (LEGN): stock profile, AI score and financials

Legend Biotech Corp (LEGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEGN at 29.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,485 of 2,925 stocks — the bottom half of the AI-ranked universe. LEGN scores in the top quartile across institutional flow (84.7). Areas of concern include profitability (7.3) and free cash flow (7.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q4 2025), Legend Biotech Corp reports quarterly revenue of $973.5M, net income of $-30.8M, an operating margin of -2.0%. Top institutional holders of LEGN by reported 13-F value include FMR, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), SUVRETTA CAPITAL MANAGEMENT, based on the most recent SEC filings. LEGN trades on the Nasdaq exchange and files with the SEC under CIK 1801198. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Legend Biotech Corp directly from SEC EDGAR.

SEC EDGAR: CIK 1801198 →